1. C3.ai faces a class action lawsuit for misleading financial statements. 2. Investors were misled about revenue projections and CEO health risks. 3. The lawsuit alleges significant investor losses due to false marketing. 4. Potential poor earnings impact due to mismanaged investor expectations. 5. Investors can seek compensation if involved during the class period.
The allegations of misleading investors could diminish trust and stock value, reminiscent of past class actions that resulted in significant losses for companies involved.
The lawsuit has significant implications for C3.ai’s credibility, potentially affecting AI market sentiment.
Immediate investor sentiment could turn negative, impacting stock price quickly, as seen in previous cases like Valeant Pharmaceuticals.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against C3.ai, Inc. ("C3" or "the Company") (NYSE: AI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between February 26, 2025 and August 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before October 21, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. C3 led investors to believe it could reliably project its revenues and growth. The Company also minimized the risk to its operations posed by the health concerns of CEO Thomas M. Siebel. The company's optimistic projections for growth, earnings, and margin failed to materialize, which it in part blamed on its CEO's health issues. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about C3, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250825685646/en/
The Schall Law Firm
Brian Schall, Esq.
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com